BTIG analyst Ryan Zimmerman raised the firm’s price target on Zimmer Biomet (ZBH) to $122 from $118 and keeps a Buy rating on the shares as part of a broader research note previewing Q3 results for MedTech industry. Headlines weighing on sentiment in MedTech include cuts to Medicaid, ACA subsidies not being renewed, and concerns on the broader economy, as investors fear that fewer patients may seek out medical treatment, while the latest threat of high tariffs on China imports adds to uncertainty, but even so, the results in Q may prove better than feared as much of the headline risk is slated to take effect further in the future, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target lowered to $111 from $115 at RBC Capital
- Zimmer Biomet Acquires Monogram Technologies to Enhance Robotics
- Zimmer Biomet completes acquisition of Monogram Technologies
- Zimmer Biomet’s Innovative Hip System Gains Approval in Japan, But Hold Rating Maintained Amid Uncertainty
- Zimmer Biomet’s hip replacement system approved by Japan’s PMDA